BRIEF—India could blacklist eight Chinese suppliers, triggering drug shortages

India has issued warnings to eight Chinese pharmaceutical companies, and may soon blacklist them for supplying low-grade raw materials to local manufacturers.

Indian press reports that warnings were issued after inspectors visited the companies in China.

The eight companies are Guangzhao Baiyunshan Pharmaceuticals, Shouguang Fukang Pharmaceuticals, Qilu Antibiotics (Linyi) Pharmaceuticals, Qindao Brightmoon Seawoods, Shanghaoi Xiandia Hasen (Shangqiu) Pharmaceuticals, Qilu Tianhe Pharmaceuticals, Hinan Xinxiang Pharmaceuticals and Zhuhai United Laboratories.

India imports 70% of the raw materials for its drugs from China. If the companies are blacklisted, the country is expected to experience drug shortages that could last up to three months.